A few months after SK Life Science began rolling out a road trip-themed TV commercial for its antiseizure medication Xcopri, the FDA is attempting to put the brakes on the ad.

Novo Nordisk has come up short in two phase 3 trials of semaglutide as a treatment for Alzheimer’s disease. But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo’s shares fell by nearly 9% at the U.S. market open Monday.

A combination of Merck-partnered sac-TMT and Keytruda led to a “statistically significant and clinically meaningful” improvement in progression-free survival versus Keytruda alone in a phase 3 trial in first-line PD-L1-positive NSCLC, Kelun said Monday.

Maryland is becoming the home away from home for British drugmaker AstraZeneca. On Friday, the biopharma powerhouse upped its ante in the Old Line State, saying it will invest $2 billion to increase its manufacturing presence there.

The approval came “months earlier than anticipated,” Pfizer’s Chief Oncology Officer, Jeff Legos, Ph.D., said in a statement.

Texas Attorney General Ken Paxton filed a lawsuit Thursday on behalf of the state that takes aim at “false, misleading, and deceptive” marketing practices that Sanofi and Bristol Myers Squibb allegedly engaged in to sell blood thinner Plavix.